Pathologist: Omer Iqbal, MD | Loyola Medicine

Omer Iqbal, MD

Pathology

Research Professor

Languages Spoken

English, Telugu,Hindi,Indian,French

Clinical Expertise

  • Diagnosis Of Bleeding Or Clotting Disorders
  • Diagnosis Of Blood Disorders

About Dr. Iqbal

Interests
Bicycling, Hiking

Medical Education

Medical School
Gandhi Medical College, India
Residency
Fellowship

Board Certification

Research

  • Prevalence of metabolic syndrome in patients undergoing total joint arthroplasty and relevance of biomarkers Saluk, J. L.; Banos, A. L.; Hopkinson, W. L.; Rees, H. L.; Syed, D.; Hoppensteadt, D.; Abro, S.; Iqbal, O.; Fareed, J., International angiology : a journal of the International Union of Angiology
  • The Protective Effect of Poloxamer-188 on Platelet Functions Guler, N.; Abro, S.; Emanuele, M.; Iqbal, O.; Hoppensteadt, D.; Fareed, J., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Elevated endocan levels and its association with clinical severity in Stevens-Johnson Syndrome and toxic epidermal necrolysis Syed, D.; Iqbal, O.; Mosier, M.; Mitchell, R.; Hoppensteadt, D.; Bouchard, C.; Fareed, J.; Gamelli, R., International angiology : a journal of the International Union of Angiology
View All ResearchShow Less
  • Immunoenzymatic and Biochip Array Profiling of the Biomarkers of Inflammation and Hemostatic Activation Processes in ESRD Richards, J.; Bansal, V.; Iqbal, O.; Hoppensteadt, D.; Fareed, J., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Comparative Biochemical and Functional Studies on a Branded Human Recombinant Factor VIIa and a Biosimilar Equivalent Product Sadeghi, N.; Kahn, D.; Syed, D.; Iqbal, O.; Abro, S.; Eshraghi, R.; Hoppensteadt, D.; Fareed, J., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Increased expression of secreted frizzled-related protein-1 and microtubule-associated protein light chain 3 in keratoconus Iqbal, O.; Fisher, G.; Vira, S.; Syed, D.; Sadeghi, N.; Freeman, D.; Campbell, E.; Sugar, J.; Feder, R.; Fareed, J.; Bouchard, C., Cornea
  • A consensus conference on complex biologics and low molecular weight heparin Kalodiki, E.; Fareed, J.; Tapson, W. F.; Hoppensteadt, D. A.; Carter, C. A.; Sussman, I.; Parker, S.; Harenberg, J.; Hull, R.; Rao, G.; Lovinger, D. F.; Reid, L. D.; Kakkar, A.; Talarico, L.; Ofosu, F. A.; Bussey, H. I.; Fanikos, J.; Groce, J. B.; Skinner, N.; Ahluwalia, M.; Iqbal, O.; Jackson, C. M.; Jeske, W. P.; Ramacciotti, E.; Van Thiel, D.; Wahi, R.; Walenga, J., International Angiology
  • Clopidogrel provides significantly greater inhibition of platelet activity than aspirin when combined with atorvastatin after coronary artery bypass grafting: a prospective randomized study. Tetik, S.; Ak, K.; Isbir, S.; Eksioglu-Demiralp, E.; Arsan, S.; Iqbal, O.; Yardimci, T., Clinical & Applied Thrombosis/Hemostasis
  • P-selectin in major depression: preliminary findings with venlafaxine treatment Piletz, J. E.; Halaris, A.; Iqbal, O.; Hoppensteadt, D.; Fareed, J.; Zhu, H.; Sinacore, J.; DeVane, C. L., International Journal of Health Science
  • Comparative anticoagulant and platelet modulatory effects of enoxaparin and sulodexide. Adiguzel, C.; Iqbal, O.; Hoppensteadt, D.; Jeske, W.; Cunanan, J.; Litinas, E.; He, Z.; Walenga, J. M.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Effect of bosentan on plasma markers of endothelial cell activity in patients with secondary pulmonary hypertension related to connective tissue diseases. Cella, G.; Vianello, F.; Cozzi, F.; Marotta, H.; Tona, F.; Saggiorato, G.; Iqbal, O.; Fareed, J., Journal of Rheumatology
  • European community and US-FDA approval of recombinant human antithrombin produced in genetically altered goats. Adiguzel, C.; Iqbal, O.; Demir, M.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Increased prevalence of antiheparin platelet factor 4 antibodies in patients may be due to contaminated heparin. Adiguzel, C.; Bansal, V.; Litinas, E.; Cunanan, J.; Iqbal, O.; Nelson, K.; Kannan, M.; Hoppensteadt, D.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Nitric oxide branch of arginine metabolism in depression: effect of venlafaxine Piletz, J. E.; Halaris, A.; Iqbal, O.; Hoppensteadt, D.; Fareed, J.; Zhu, H.; Sinacore, J.; DeVane, C. L., International Journal of Health Science
  • Pro-inflammatory biomakers in depression: treatment with venlafaxine. Piletz, J. E.; Halaris, A.; Iqbal, O.; Hoppensteadt, D.; Fareed, J.; Zhu, H.; Sinacore, J.; Devane, C. L., World Journal of Biological Psychiatry
  • Relative purity of different bovine thrombin preparations. Zhu, H.; Hoppensteadt, D.; Iqbal, O.; Litinas, E.; Adiguzel, C.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • SASAT (South Asian Society on Atherosclerosis & Thrombosis) proposal for regulatory guidelines for generic low-molecular weight heparins (LMWHs). Kalodiki, E.; Leong, W.; Iqbal, O., Clinical & Applied Thrombosis/Hemostasis
  • Argatroban in percutaneous coronary indications Iqbal, O.; Adiguzel, C.; Lewis, B. E.; Cunanan, J.; Fareed, J., Seminars in Thrombosis and Hemostasis
  • Biological Profile of the Hyper/Oversulfated Chondroitin Sulfate Contaminant Isolated from Recalled Heparin Fareed, J.; Walenga, J. M.; Jeske, W. P.; Hoppensteadt, D.; Prechel, M.; Iqbal, O.; Adiguzel, C.; Clark, M.; Litinas, E.; cunanan, J.; Linhardt, R.; Harenberg, J., Seminars in thrombosis and hemostatis
  • Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged? Fareed, J.; Iqbal, O.; Cunanan, J.; Demir, M.; Wahi, R.; Clarke, M.; Adiguzel, C.; Bick, R., International Angiology
  • Contaminant in the recalled unfractionated heparin preparations: where is the problem?. Hoppensteadt, D. A.; Wahi, R.; Adiguzel, C.; Iqbal, O.; Ramacciotti, E.; Bick, R. L.; Messmore, H. L.; Bansal, V.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Molecular profiling of heparinase-I resistant glycosaminoglycans in contaminated heparins. Comparative studies with uncontaminated heparin and porcine oversulfated chondroitin sulfate. Clark, M.; Hoppensteadt, D.; Walenga, J. M.; Myers, L.; Cunanan, J.; Jeske, W.; Adiguzel, C.; Iqbal, O.; Fareed, J., International Angiology
  • Potency Adjusted Generic Versions of Argatroban can be Differentiated from Branded Argatroban in Thrombin Generation and Platelet Activation Assays Adiguzel, C.; Iqbal, O.; Cunanan, J.; Jeske, W.; Hoppensteadt, D.; Walenga, J. M.; Fareed, J., Seminars in Thrombosis and Hemostasis
  • Protective gene variant of GRK5 in African–Americans with chronic heart failure associated with improved survival Iqbal, O.
  • Rivaroxaban--an oral direct Factor Xa inhibitor--has potential for the management of patients with heparin-induced thrombocytopenia., Walenga, J. M.; Prechel, M.; Jeske, W. P.; Hoppensteadt, D.; Maddineni, J.; Iqbal, O.; Messmore, H. L.; Bakhos, M., British journal of haematology
  • Plasma thrombin activatable fibrinolysis inhibitor and tissue factor pathway inhibitor changes following sepsis. Ravindranath, T. M.; Goto, M.; Iqbal, O.; Florian-Kujawski, M.; Hoppensteadt, D.; Hammadeh, R.; Sayeed, M. M.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Clinical applications of bioinformatics genomics, and pharmacogenomics, Iqbal, O.; Fareed, J., Methods in Molecular Biology
  • Comparative tissue factor pathway inhibitor release potential of heparins. Tobu, M.; Ma, Q.; Iqbal, O.; Schultz, C.; Jeske, W.; Hoppensteadt, D. A.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Pharmacogenomics and pharmacogenetics. 1st Spanish Congress on Pharmacogenomics and Pharmacogenetics January 23-25, 2005, Valencia, Spain., Iqbal, O., Pharmacogenomics
  • Successful use of recombinant hirudin and its monitoring by ecarin clotting time in patients with heparin-induced thrombocytopenia undergoing off-pump coronary artery revascularization. Iqbal, O.; Tobu, M.; Aziz, S.; Gerdisch, M.; Da Valle, M.; Demir, M.; Hoppensteadt, D. A.; Ahmad, S.; Walenga, J. M.; Fareed, J., Journal of cardiac surgery
  • A survey of venous thrombosis models Jeske, W. P.; Iqbal, O.; Fareed, J.; Kaiser, B., Methods in Molecular Medicine
  • Anti-Xa and anti-IIa drugs alter international normalized ratio measurements: potential problems in the monitoring of oral anticoagulants. Tobu, M.; Iqbal, O.; Hoppensteadt, D.; Neville, B.; Messmore, H. L.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Antiplatelet anticoagulant, and thrombolytic drug interactions., Iqbal, O.; Mousa, S. A., Methods in Molecular Medicine
  • Blood levels of nitric oxide C-reactive protein, and tumor necrosis factor-alpha are upregulated in patients with malignancy-associated hypercoagulable state: pathophysiologic implications., Fareed, D.; Iqbal, O.; Tobu, M.; Hoppensteadt, D. A.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Differentiation of low-molecular-weight heparins: impact on the future of the management of thrombosis Fareed, J.; Ma, Q.; Florian, M.; Maddineni, J.; Iqbal, O.; Hoppensteadt, D. A.; Bick, R. L., Seminars in Thrombosis & Hemostasis
  • Erythropoietin-induced thrombosis as a result of increased inflammation and thrombin activatable fibrinolytic inhibitor. Tobu, M.; Iqbal, O.; Fareed, D.; Chatha, M.; Hoppensteadt, D.; Bansal, V.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Pharmacogenomics and coagulation disorders Iqbal, O., Methods in Molecular Medicine
  • Global anticoagulant effects of a synthetic anti-factor Xa inhibitor (DX-9065a): implications for interventional use. Tobu, M.; Iqbal, O.; Ma, Q.; Schultz, C.; Jeske, W.; Hoppensteadt, D.; Lewis, B.; Fareed, D.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Influence of different anticoagulant agents on fibrinopeptide a generation. Tobu, M.; Iqbal, O.; Messmore, H. L.; Ma, Q.; Hoppensteadt, D. A.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practice Fareed, J.; Hoppensteadt, D.; Walenga, J. M.; Iqbal, O.; Ma, Q.; Jeske, W.; Sheikh, T., Clinical pharmacokinetics
  • Emerging anticoagulant and thrombolytic drugs Iqbal, O.; Aziz, S.; Hoppensteadt, D. A.; Ahmad, S.; Walenga, J. M.; Bakhos, M.; Fareed, J., Expert opinion on emerging drugs
  • Bleeding complications with glycoprotein IIb/IIIa inhibitors Iqbal, O.; Walenga, J. M.; Lewis, B. E.; Bakhos, M., Drugs of today (Barcelona, Spain : 1998)